


OSE Immunotherapeutics Presents Update on BiCKI®-IL-7v and CLEC-1 Immuno-Oncology Programs at International Conferences

Immutep Announces Independent Data Monitoring Committee Positive
Recommendation to Continue TACTI-003 Trial as Planned

ERYTECH reçoit une notification du Nasdaq

Domain Therapeutics to progress into clinical trials with its EP4R antagonist DT-9081 in solid tumors
